Abstract
Background Exogenous stem cell therapy has shown benefits for treating peripheral arterial disease patients, who are not amenable for conventional revascularization therapy. Previously, we have demonstrated the ability of imaging-visible cell microencapsulation to overcome the challenges of poor cell retention/survival and difficulties with monitoring cell delivery success. However, in vivo cell viability cannot be assessed noninvasively. Here, we investigate the potential of PET-MRI tracking of F MRI-visible microencapsulated human mesenchymal stem cells (hMSCs) labeled with triple-fusion (TF) reporter gene in non-immunosuppressed rabbits.
Highlights
Exogenous stem cell therapy has shown benefits for treating peripheral arterial disease patients, who are not amenable for conventional revascularization therapy
Rabbits received either intramuscular injection of PFOB-encapsulated TF-human mesenchymal stem cells (hMSCs) in the medial thigh followed by intravenous administration of [18F] 9-[4-fluoro-3-(hydroxymethy) butyl] guanine ([18F]FHBG) (n=7, 1.7±0.7 mCi), or PFOB-encapsulated TFhMSCs that were pre-incubated with [18F]-FHBG (n=3, 55±2 μCi)
In vitro hMSC viability and transgene expression were not affected by encapsulation or [18F]-FHBG incubation as determined by BLI and live/dead cell staining (91±6%)
Summary
PET-MRI tracking of imaging-visible microencapsulated stem cells in immunocompetent rabbits. Yingli Fu1*, Ronnie Mease, Ying Chen, Guan Wang, Dorota Kedziorek, Meiyappan Solaiyappan, Dara Kraitchman. From 16th Annual SCMR Scientific Sessions San Francisco, CA, USA. From 16th Annual SCMR Scientific Sessions San Francisco, CA, USA. 31 January - 3 February 2013
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
